Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 36% ± 9% | |
ciliated cell | 3 studies | 26% ± 2% |
Insufficient scRNA-seq data for expression of FUNDC1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 1302.94 | 2642 / 2642 | 100% | 53.19 | 705 / 705 |
ovary | 100% | 695.66 | 180 / 180 | 100% | 36.59 | 430 / 430 |
prostate | 100% | 628.15 | 245 / 245 | 100% | 50.46 | 502 / 502 |
esophagus | 100% | 533.35 | 1444 / 1445 | 100% | 28.85 | 183 / 183 |
breast | 100% | 589.21 | 459 / 459 | 100% | 63.67 | 1114 / 1118 |
adrenal gland | 100% | 787.52 | 258 / 258 | 100% | 66.90 | 229 / 230 |
uterus | 100% | 587.92 | 170 / 170 | 100% | 58.36 | 457 / 459 |
kidney | 100% | 737.74 | 89 / 89 | 100% | 39.60 | 897 / 901 |
thymus | 100% | 651.00 | 653 / 653 | 100% | 47.43 | 602 / 605 |
bladder | 100% | 530.62 | 21 / 21 | 99% | 46.37 | 501 / 504 |
intestine | 100% | 466.67 | 966 / 966 | 99% | 37.10 | 522 / 527 |
skin | 100% | 675.56 | 1806 / 1809 | 99% | 42.38 | 468 / 472 |
stomach | 100% | 756.35 | 358 / 359 | 99% | 37.28 | 283 / 286 |
lung | 97% | 419.93 | 560 / 578 | 100% | 43.86 | 1154 / 1155 |
pancreas | 94% | 256.22 | 309 / 328 | 99% | 39.49 | 176 / 178 |
liver | 91% | 222.38 | 205 / 226 | 92% | 19.71 | 374 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 47.93 | 29 / 29 |
spleen | 100% | 539.25 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 41.99 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 30.35 | 1 / 1 |
adipose | 100% | 501.91 | 1201 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 520.53 | 1327 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 31.98 | 78 / 80 |
muscle | 97% | 361.47 | 778 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 809.09 | 831 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 58% | 283.73 | 538 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000422 | Biological process | autophagy of mitochondrion |
GO_0000423 | Biological process | mitophagy |
GO_0001666 | Biological process | response to hypoxia |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0005515 | Molecular function | protein binding |
Gene name | FUNDC1 |
Protein name | FUN14 domain-containing protein 1 |
Synonyms | |
Description | FUNCTION: Integral mitochondrial outer-membrane protein that mediates the formation of mitochondria-associated endoplasmic reticulum membranes (MAMs) . In turn, mediates angiogenesis and neoangiogenesis through interference with intracellular Ca(2+) communication and regulation of the vascular endothelial growth factor receptor KDR/VEGFR2 expression at both mRNA and protein levels . Acts also as an activator of hypoxia-induced mitophagy, an important mechanism for mitochondrial quality and homeostasis, by interacting with and recruiting LC3 protein family to mitochondria . Mechanistically, recruits DRP1 at ER-mitochondria contact sites leading to DRP1 oligomerization and GTPase activity to facilitate mitochondrial fission during hypoxia . Additionally, plays a role in hepatic ferroptosis by interacting directly with glutathione peroxidase/GPX4 to facilitate its recruitment into mitochondria through TOM/TIM complex where it is degraded by mitophagy . . |
Accessions | Q8IVP5 ENST00000378045.5 |